MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Home・Akcijų sąrašas・Cogent Biosciences Inc

Cogent Biosciences Inc

Uždarymo kaina

37.63 7.15

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.72

Max

38.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.4M -81M
Pelnas, tenkantis vienai akcijai	-0.5
Darbuotojai	205
EBITDA	-6.8M -79M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+44.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.2B 5.3B
Ankstesnė atidarymo kaina	30.48
Ankstesnė uždarymo kaina	37.63

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

4.88 / 5.87 Palaikymas ir pasipriešinimas

Cogent Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-14 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026-01-15 00:00; UTC

Uždarbis

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026-01-14 23:47; UTC

Rinkos pokalbiai

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026-01-14 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026-01-14 23:39; UTC

Rinkos pokalbiai

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026-01-14 23:32; UTC

Rinkos pokalbiai

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-14 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026-01-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026-01-14 22:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-14 22:17; UTC

Rinkos pokalbiai

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026-01-14 22:09; UTC

Uždarbis

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026-01-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Announces Positive Profit Alert for 2025

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup Acting as Financial Advisor to WuXi XDC

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026-01-14 21:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-01-14 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-14 21:49; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Makes Cash Offer for BioDlink International

2026-01-14 21:13; UTC

Rinkos pokalbiai

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026-01-14 20:30; UTC

Rinkos pokalbiai

Uždarbis

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026-01-14 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026-01-14 20:08; UTC

Rinkos pokalbiai

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026-01-14 19:33; UTC

Rinkos pokalbiai

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026-01-14 19:06; UTC

Rinkos pokalbiai

Uždarbis

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Akcijų palyginimas

Kainos pokytis

Cogent Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

44.56% į viršų

12 mėnesių prognozė

Vidutinis 50.25 USD 44.56%

Aukščiausias 67 USD

Žemiausias 34 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cogent Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Cogent Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.88 / 5.87Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.